|
| N | Mean OS (months) | Overall Survival (OS) | p-value†| |||
| Estimate | (95% CI) | 1-year | 2-year | 3-year | |||
| All patients | 70 | 28.22 month | (24.92 - 31.52) | 83.2% | 67.3% | 67.3% | ----- |
| Grade |
|
|
|
|
|
|
|
| Low | 18 | 32.09 month | (28.38 - 35.80) | 93.8% | 82% | 82% | 0.063 |
| High | 52 | 26.51 month | (22.34 - 30.68) | 79.5% | 63.1% | 63.1% |
|
| LN |
|
|
|
|
|
|
|
| Negative | 22 | 35.00 month | (33.17 - 36.88) | 100% | 92.3% | 92.3% | <0.001 |
| Positive | 48 | 16.07 month | (14.10 - 18.03) | 74.6% | ----- | ----- |
|
| Stage |
|
|
|
|
|
|
|
| Stage I | 8 | 36.00 month | ----- | 100% | 100% | 100% | 0.019 |
| Stage II | 12 | 30.97 month | (27.20 - 34.75) | 100% | 78.6% | ----- |
|
| Stage III | 32 | 17.05 month | (14.79 - 19.32) | 79.3% | ----- | ----- |
|
| Stage IV | 18 | 12.69 month | (10.47 - 14.90) | 68.8% | ----- | ----- |
|
| Gal-1 |
|
|
|
|
|
|
|
| Weak | 22 | 35.00 month | ----- | 100% | 100% | 100% | 0.002 |
| Strong | 48 | 24.22 month | (19.67 - 28.77) | 75.5% | 49.5% | 49.5% |
|
| Gal-1 tumor cells |
|
|
|
|
|
|
|
| Weak | 24 | 31.60 month | (28.02 - 35.19) | 87.1% | 87.1% | 87.1% | 0.064 |
| Strong | 46 | 25.10 month | (20.33 - 29.87) | 81.2% | 51.9% | 51.9% |
|